Piedra, A, Guinart-Cuadra, A, Recio, SM, Mulet, M, Atenza, CZ, Alejandre, J, Beltran, JS, Joaquín, AB, Sullivan, IG, López, JS, Casado, MDI, Aperribay, EA, Paz-Ares, L, Tain, PD, Vega, ALM, Callejo, A, Martos, JLL, Dominguez, M, Vidal, S, Majem, M. Baseline PD-L1 expression in circulating neutrophils predicts immune-related adverse events (irAEs) in patients with extensive-stage small-cell lung cancer from CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, O'Byrne, KJ, Lo Russo, G, Mueller, C, Triebel, F. TACTI-004: A double-blinded, randomized phase III trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo plus P plus C. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Gillessen, S, Tombal, B, Turco, F, Choudhury, A, Rodriguez-Vida, A, Gallardo, E, Velho, PI, Nolè, F, Cruz, F, Loriot, Y, McDermott, R, Roumeguere, T, Daugaard, G, Yamamura, R, Bompas, E, Maroto, P, Polo, MH, da Trindade, KM, Preto, DD, Skoneczna, I, Lecouvet, F, Coens, C, Fournier, B, Saad, F. Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. EUROPEAN UROLOGY. 2025; 87(3)DOI:10.1016/j.eururo.2024.11.027. PMID:39827019. IF:25.200(Q1/1D).

Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, MCM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Patient-reported outcomes from CANTABRICO: Durvalumab plus platinum-etoposide in first-line treatment of extensive stage small cell lung cancer. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Majem, M, Gregorc, V, Lo Russo, G, Maio, M, Salvagni, S, Calderon, VG, Cao, MG, Contreras, SS, Koumarianou, A, Bearz, A, Caro, RB, Viteri, S, Sanmamed, MF, Zagouri, F, Bueno, MTM, Zhang, Y, Shan, Y, Zhu, H, Rosell, R. First-line (1L) fulzerasib plus cetuximab in KRAS G12Cm advanced NSCLC: Updated efficacy and safety from KROCUS study. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Casado, MDI, Aperribay, EA, Campelo, MRG, Blanco, CM, Tain, PD, Piqueras, MMLB, Vega, ALM, Mateos, LAL, Rodriguez, JMO, Calderon, VG, Majem, M, Hernandez, AS, de la Rosa, CA, Cabellos, RA, Sureda, BM, Baret, M, Martos, JLL, Dominguez, M, Paz-Ares, L. Long-term survivors with extensive-stage small-cell lung cancer treated with first-line durvalumab plus carboplatin and etoposide: The CANTABRICO trial. Journal of Thoracic Oncology. 2025; 20(3)DOI:. PMID:. IF:20.800(Q1/1D).

Rueda-Lara, A, Viñal, D, Martínez-Pérez, D, Alameda-Guijarro, M, Martin-Montalvo, G, Martínez-Recio, S, Peña-Lopez, J, Jiménez-Bou, D, Ruíz-Gutiérrez, I, García-Leal, A, Zwisler-Contreras, P, Ghanem, I, Custodio, AB, Pérez-Wert, P, Gutiérrez-Sainz, L, Palacios, ME, Feliu, J, Rodríguez-Salas, N. Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital. ONCOLOGIST. 2025; 30(3)DOI:10.1093/oncolo/oyaf027. PMID:40152315. IF:4.200(Q2/3D).

Szafranska, J, Batto, V, Alcaraz, J, Guinart-Cuadra, A, Brujats, A, Fajardo, J, Acin, V, Garcia, H, Casani, L, Villanueva, C, Ferré, M, del Olmo, TV, Tapias, EA. CT-FIRE a Novel Technique in Quantitative Image Analysis of Collagen Fibers in Chronic Liver Disease Regression Animal Model. LABORATORY INVESTIGATION. 2025; 105(3)DOI:10.1016/j.labinv.2024.103704. PMID:. IF:4.200(Q1/1D).